Clinical Trials Directory

Trials / Unknown

UnknownNCT05995093

The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation

Status
Unknown
Phase
Study type
Observational
Enrollment
462 (estimated)
Sponsor
Qilu Hospital of Shandong University · Academic / Other
Sex
All
Age
18 Years – 94 Years
Healthy volunteers
Not accepted

Summary

The project was undertaking by Qilu Hospital of Shandong University, aiming to evaluate diagnostic performance of hemostatic biomarkers in disseminated intravascular coagulation.

Detailed description

Disseminated intravascular coagulation (DIC) is a life-threatening condition with high mortality, necessitating timely and accurate diagnosis for effective management. However, current diagnostic systems can not recognize DIC at its reversible phase, causing suboptimal treatment outcomes. Consequently, the current diagnostic criteria for DIC lacks earlier laboratory indicators. Therefore, the investigators aimed to assess the diagnostic potential of selected hemostatic biomarkers, including thrombin-antithrombin complex (TAT), soluble thrombomodulin (sTM), tissue plasminogen activator inhibitor complex (tPAI-C), α2-plasmin inhibitor plasmin complex (PIC) and anti-thrombin III (ATIII), in evaluating DIC, allowing for proactive diagnosis before the disease progresses into its irreversible phase.

Conditions

Interventions

TypeNameDescription
OTHERno interventionno intervention

Timeline

Start date
2022-12-01
Primary completion
2023-12-31
Completion
2024-06-30
First posted
2023-08-16
Last updated
2023-10-24

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05995093. Inclusion in this directory is not an endorsement.